Yes, a good day. Hopefully will finish the week strong.
The results for 42-X were about as good as can be expected for a phase 2 trial. To my knowledge this drug was never expected or intended to be a cure for OSA but an alternative for patients who can't use CPAP machines, or for use alongside other, less invasive treatments to support efficacy. The size of the trial shouldn't have surprised anyone as it was always part of the design and public information. Even if this drug was only suitable for 10% of OSA sufferers it would still be a significant revenue stream for the company. There are plenty of drugs that only work for a % of patients.
